A significant tool to achieve Personalized Medicine is the availability of repositories of freely accessible databases. Large databases are formed containing information from genomic, transcriptomic, and proteomic analyses which is available for global access and data processing. Some of these include the Cancer Genome Anatomy Project, the Single Nucleotide Polymorphism Database, in addition to many others. Bioinformatics algorithms can then be used to integrate a patient's clinical information and the genetic profiles of their tumor to predict the relationships of certain molecular changes to the cancer.
Standardization of Personalized medicine includes several characteristics including the type of sample to be analyzed, the suitable methods of sample collection and storage, the selection of the target genes/proteins to be tested, the platform to be used, best experimental conditions, and the interpretation of tests. There are specific quality standards for different laboratories, and test validations will be required with external quality assurance protocols.
There are different approaches and tools available for molecular Personalized Medicine testing. A large array of techniques can be used for Personalized Medicine. Commonly used techniques include PCR, fluorescence in situ hybridization and sequencing. Recently, the completion of the human genome project opened a new opportunities for Personalize Medicine analysis by using high-throughput analysis. These include microarray, mass spectrometry, second-generation sequencing, array comparative genomic hybridization, and high-throughput SNP analysis, among others. A common trend among these tools is their ability to simultaneously analyze hundreds or thousands of targets. This multipara metric approach is likely to improve the sensitivity, specificity, and accuracy of new biomarkers. In addition to acceleration of biomarker discovery, high-throughput analysis allows a better understanding of interaction between different molecules in the pathogenesis of cancer.
The overall market generated revenue of $xx m in 2015 and is expected to grow with CAGR of xx% throughout the forecast period to generate $xx m by 2021. The Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Currently Americas and Europe region dominate the overall market by contributing to xx% of the overall revenue. These regions are growing with CAGR of xx% and xx% respectively throughout the forecast period.
The Key biotechnology and pharmaceutical companies such as Caris Life Sciences (U.S.), Proteome Sciences PLC (U.K.), Life Technologies (U.S.), Boreal Genomics, Inc. (U.S.), Oxford Gene Technology Ltd. (OGT) (U.K.), and Precision Therapeutics, Inc. (U.S.), among others, are undertaking various strategically decisions such as collaborating and partnering with each other as well as with research universities to develop cancer profiling products.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Personalized Medicines In Oncology Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Personalized Medicines In Oncology Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
4.3. Attractiveness of the Personalized Medicines In Oncology Market
4.3.1. Power of Suppliers
4.3.2. Threats From New Entrants
4.3.3. Power of Buyer
4.3.4. Threat From Substitute Product
4.3.5. Degree of Competition
5. Personalized Medicines In Oncology -Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product Life Cycle
5.5. Suppliers and Distributors
6. Personalized Medicines In Oncology- By Tumore Type
7. Personalized Medicines In Oncology- By Service
7.1. Molecular Oncopathology
7.2. Genome Diagnostics
7.3. Radiation Therapy
7.4. Oncology Testing
8. Personalized Medicines In Oncology- By Occurence
8.1. Colorectal/ stomach/ esophageal
9. Personalized Medicines In Oncology- By Technology
9.1. Next-Generation Sequencing
9.2. Fluorescence/ Chromogenic In Situ Hybridization
9.5. Quantitative PCR
9.6. High Throughput SNP Analysis
10. Personalized Medicines In Oncology- By End User
10.1. Research Centers
10.2. Governmental Institutions
11. Personalized Medicines In Oncology- Geography
11.3. Asia Pacific
11.3.3. Australia & New Zealand
11.4. Rest of The World (RoW)
11.4.1. Middle East
12. Personalized Medicines In Oncology Entropy
12.1. New Product Developments
12.2. Product Launches, JVs, Mergers and Acquisitions
13. Company Profiles
13.1. Agendia Nv
13.2. Allere Laboratory
13.3. Alpha Genomix
13.4. Ariana Pharma
13.8. Boreal Genomics, Inc.
13.9. Caris Life Sciences
13.10. Chordoma Foundation
13.12. Cypher Genomics
13.13. deCode Genetics
13.15. DNA Link
13.16. Edge Bio
13.17. Foundation Medicine
13.18. Fulgent Diagnostics
13.19. Gene TLC
13.21. Genomic Engenharia Molecular
13.22. Genomic Health, Inc.
13.23. Illumina, Inc.
13.24. Life Technologies Corporation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"